Dyne Therapeutics, Inc. $DYN Stock Holdings Increased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC boosted its position in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 5.1% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 51,011 shares of the company’s stock after buying an additional 2,495 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Dyne Therapeutics were worth $486,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC increased its holdings in Dyne Therapeutics by 168.1% in the second quarter. CWM LLC now owns 3,030 shares of the company’s stock valued at $29,000 after buying an additional 1,900 shares during the last quarter. Aberdeen Group plc boosted its stake in Dyne Therapeutics by 53.8% in the second quarter. Aberdeen Group plc now owns 483,963 shares of the company’s stock valued at $4,607,000 after acquiring an additional 169,377 shares during the period. KLP Kapitalforvaltning AS grew its holdings in shares of Dyne Therapeutics by 39.4% during the second quarter. KLP Kapitalforvaltning AS now owns 15,200 shares of the company’s stock valued at $145,000 after purchasing an additional 4,300 shares during the last quarter. 111 Capital bought a new position in shares of Dyne Therapeutics during the second quarter valued at approximately $147,000. Finally, Compagnie Lombard Odier SCmA grew its holdings in shares of Dyne Therapeutics by 157.1% during the second quarter. Compagnie Lombard Odier SCmA now owns 18,000 shares of the company’s stock valued at $171,000 after purchasing an additional 11,000 shares during the last quarter. 96.68% of the stock is owned by institutional investors.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox sold 2,640 shares of the company’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $13.41, for a total value of $35,402.40. Following the completion of the sale, the chief executive officer directly owned 199,539 shares in the company, valued at $2,675,817.99. This represents a 1.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 20.77% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on DYN shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Wednesday, October 8th. Chardan Capital lowered their target price on Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating for the company in a report on Tuesday, July 29th. Raymond James Financial raised Dyne Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their target price for the company from $31.00 to $35.00 in a report on Monday, August 25th. Stifel Nicolaus lowered their target price on Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, July 31st. Finally, Royal Bank Of Canada lowered their target price on Dyne Therapeutics from $25.00 to $23.00 and set an “outperform” rating for the company in a report on Tuesday, July 29th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.07.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $24.29 on Wednesday. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $35.68. The firm has a market capitalization of $3.46 billion, a price-to-earnings ratio of -6.29 and a beta of 1.09. The business has a 50 day simple moving average of $14.28 and a 200 day simple moving average of $12.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.02. On average, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.